vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and ORMAT TECHNOLOGIES, INC. (ORA). Click either name above to swap in a different company.

ORMAT TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($276.0M vs $168.4M, roughly 1.6× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 19.6%). Over the past eight quarters, ORMAT TECHNOLOGIES, INC.'s revenue compounded faster (11.0% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Ormat Technologies, Inc. is an international company based in Reno, Nevada, United States. Ormat supplies alternative and renewable geothermal energy technology. The company has built over 190 power plants and installed over 3,200 MW of output. As of January 2021 it owns and operates 933 MW of geothermal and recovered energy based power plants. Ormat has supplied over 1000 turbochargers worldwide, in North America, South America, Europe, Australia, and Asia. The company's products also includ...

ESPR vs ORA — Head-to-Head

Bigger by revenue
ORA
ORA
1.6× larger
ORA
$276.0M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+124.1% gap
ESPR
143.7%
19.6%
ORA
Faster 2-yr revenue CAGR
ORA
ORA
Annualised
ORA
11.0%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
ORA
ORA
Revenue
$168.4M
$276.0M
Net Profit
$31.4M
Gross Margin
28.6%
Operating Margin
50.6%
15.4%
Net Margin
11.4%
Revenue YoY
143.7%
19.6%
Net Profit YoY
-23.2%
EPS (diluted)
$0.32
$0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
ORA
ORA
Q4 25
$168.4M
$276.0M
Q3 25
$87.3M
$249.7M
Q2 25
$82.4M
$234.0M
Q1 25
$65.0M
$229.8M
Q4 24
$69.1M
$230.7M
Q3 24
$51.6M
$211.8M
Q2 24
$73.8M
$213.0M
Q1 24
$137.7M
$224.2M
Net Profit
ESPR
ESPR
ORA
ORA
Q4 25
$31.4M
Q3 25
$-31.3M
$24.1M
Q2 25
$-12.7M
$28.0M
Q1 25
$-40.5M
$40.4M
Q4 24
$40.8M
Q3 24
$-29.5M
$22.1M
Q2 24
$-61.9M
$22.2M
Q1 24
$61.0M
$38.6M
Gross Margin
ESPR
ESPR
ORA
ORA
Q4 25
28.6%
Q3 25
25.6%
Q2 25
24.3%
Q1 25
31.7%
Q4 24
31.9%
Q3 24
27.8%
Q2 24
28.8%
Q1 24
35.2%
Operating Margin
ESPR
ESPR
ORA
ORA
Q4 25
50.6%
15.4%
Q3 25
-11.4%
16.2%
Q2 25
8.6%
15.1%
Q1 25
-34.0%
22.2%
Q4 24
-6.4%
21.3%
Q3 24
-31.0%
16.8%
Q2 24
3.5%
16.5%
Q1 24
52.5%
23.5%
Net Margin
ESPR
ESPR
ORA
ORA
Q4 25
11.4%
Q3 25
-35.9%
9.7%
Q2 25
-15.4%
12.0%
Q1 25
-62.2%
17.6%
Q4 24
17.7%
Q3 24
-57.2%
10.4%
Q2 24
-83.9%
10.4%
Q1 24
44.3%
17.2%
EPS (diluted)
ESPR
ESPR
ORA
ORA
Q4 25
$0.32
$0.51
Q3 25
$-0.16
$0.39
Q2 25
$-0.06
$0.46
Q1 25
$-0.21
$0.66
Q4 24
$-0.14
$0.67
Q3 24
$-0.15
$0.36
Q2 24
$-0.33
$0.37
Q1 24
$0.34
$0.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
ORA
ORA
Cash + ST InvestmentsLiquidity on hand
$167.9M
$147.4M
Total DebtLower is stronger
$2.7B
Stockholders' EquityBook value
$-302.0M
$2.5B
Total Assets
$465.9M
$6.2B
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
ORA
ORA
Q4 25
$167.9M
$147.4M
Q3 25
$92.4M
$79.6M
Q2 25
$86.1M
$88.5M
Q1 25
$114.6M
$112.7M
Q4 24
$144.8M
$94.4M
Q3 24
$144.7M
$88.1M
Q2 24
$189.3M
$66.3M
Q1 24
$226.6M
$201.5M
Total Debt
ESPR
ESPR
ORA
ORA
Q4 25
$2.7B
Q3 25
Q2 25
Q1 25
Q4 24
$2.3B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ESPR
ESPR
ORA
ORA
Q4 25
$-302.0M
$2.5B
Q3 25
$-451.4M
$2.5B
Q2 25
$-433.5M
$2.5B
Q1 25
$-426.2M
$2.5B
Q4 24
$-388.7M
$2.4B
Q3 24
$-370.2M
$2.4B
Q2 24
$-344.2M
$2.4B
Q1 24
$-294.3M
$2.4B
Total Assets
ESPR
ESPR
ORA
ORA
Q4 25
$465.9M
$6.2B
Q3 25
$364.0M
$6.1B
Q2 25
$347.1M
$6.0B
Q1 25
$324.0M
$5.8B
Q4 24
$343.8M
$5.7B
Q3 24
$314.1M
$5.6B
Q2 24
$352.3M
$5.5B
Q1 24
$373.1M
$5.5B
Debt / Equity
ESPR
ESPR
ORA
ORA
Q4 25
1.05×
Q3 25
Q2 25
Q1 25
Q4 24
0.97×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
ORA
ORA
Operating Cash FlowLast quarter
$45.2M
$105.0M
Free Cash FlowOCF − Capex
$-40.0M
FCF MarginFCF / Revenue
-14.5%
Capex IntensityCapex / Revenue
0.0%
52.6%
Cash ConversionOCF / Net Profit
3.35×
TTM Free Cash FlowTrailing 4 quarters
$-284.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
ORA
ORA
Q4 25
$45.2M
$105.0M
Q3 25
$-4.3M
$45.2M
Q2 25
$-31.4M
$96.9M
Q1 25
$-22.6M
$88.0M
Q4 24
$-35.0M
$158.6M
Q3 24
$-35.3M
$106.4M
Q2 24
$-7.2M
$30.7M
Q1 24
$53.8M
$115.2M
Free Cash Flow
ESPR
ESPR
ORA
ORA
Q4 25
$-40.0M
Q3 25
$-102.1M
Q2 25
$-37.9M
Q1 25
$-104.6M
Q4 24
$30.9M
Q3 24
$-35.5M
$-3.3M
Q2 24
$-7.3M
$-116.1M
Q1 24
$53.8M
$11.8M
FCF Margin
ESPR
ESPR
ORA
ORA
Q4 25
-14.5%
Q3 25
-40.9%
Q2 25
-16.2%
Q1 25
-45.5%
Q4 24
13.4%
Q3 24
-68.7%
-1.6%
Q2 24
-9.9%
-54.5%
Q1 24
39.0%
5.3%
Capex Intensity
ESPR
ESPR
ORA
ORA
Q4 25
0.0%
52.6%
Q3 25
0.0%
59.0%
Q2 25
0.0%
57.6%
Q1 25
0.0%
83.8%
Q4 24
0.0%
55.4%
Q3 24
0.3%
51.8%
Q2 24
0.1%
69.0%
Q1 24
0.1%
46.1%
Cash Conversion
ESPR
ESPR
ORA
ORA
Q4 25
3.35×
Q3 25
1.87×
Q2 25
3.45×
Q1 25
2.18×
Q4 24
3.89×
Q3 24
4.82×
Q2 24
1.38×
Q1 24
0.88×
2.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

ORA
ORA

Electricity$186.6M68%
Products$63.1M23%
Energy Storage Segment$26.3M10%
Product Segment$1.2M0%

Related Comparisons